VKTX
VIKING THERAPEUTICS (VKTX) Says VK2735 Holds Weight Loss on Monthly Dosing
Maintenance study shows patients kept up to 97% of weight loss on every-other-week dosing and up to 90% on monthly dosing, with GI side effects near placebo.
VKTX
Market-moving news on Viking Therapeutics (NASDAQ: VKTX): filings, earnings, deals and other events, from REDFILED.